These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 38351139)

  • 1. Emerging role of RNA modification and long noncoding RNA interaction in cancer.
    Yang L; Tang L; Min Q; Tian H; Li L; Zhao Y; Wu X; Li M; Du F; Chen Y; Li W; Li X; Chen M; Gu L; Sun Y; Xiao Z; Shen J
    Cancer Gene Ther; 2024 Jun; 31(6):816-830. PubMed ID: 38351139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dysregulation of lncRNAs by epigenetic factors in human pathologies.
    Zhang Y; Wang X; Zhang C; Yi H
    Drug Discov Today; 2023 Sep; 28(9):103664. PubMed ID: 37348827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA modifications in long non-coding RNAs and their implications in cancer biology.
    Li J; Wang X; Wang H
    Bioorg Med Chem; 2024 Nov; 113():117922. PubMed ID: 39299080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of lncRNAs N
    Zuo L; Su H; Zhang Q; Wu WY; Zeng Y; Li XM; Xiong J; Chen LF; Zhou Y
    Aging (Albany NY); 2021 Jan; 13(3):4182-4198. PubMed ID: 33493136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Insights Into the Role of N6-Methyladenosine RNA Modification in Bone Pathophysiology.
    Chen J; Tian Y; Zhang Q; Ren D; Zhang Q; Yan X; Wang L; He Z; Zhang W; Zhang T; Yuan X
    Stem Cells Dev; 2021 Jan; 30(1):17-28. PubMed ID: 33231507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
    Liang Z; Kidwell RL; Deng H; Xie Q
    Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights into the interplay between m
    Yi YC; Chen XY; Zhang J; Zhu JS
    Mol Cancer; 2020 Aug; 19(1):121. PubMed ID: 32767982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases.
    Teng PC; Liang Y; Yarmishyn AA; Hsiao YJ; Lin TY; Lin TW; Teng YC; Yang YP; Wang ML; Chien CS; Luo YH; Chen YM; Hsu PK; Chiou SH; Chien Y
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functions of RNA N6-methyladenosine modification in cancer progression.
    Chen B; Li Y; Song R; Xue C; Xu F
    Mol Biol Rep; 2019 Apr; 46(2):2567-2575. PubMed ID: 30911972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of main RNA modifications in cancer: N
    Xue C; Chu Q; Zheng Q; Jiang S; Bao Z; Su Y; Lu J; Li L
    Signal Transduct Target Ther; 2022 Apr; 7(1):142. PubMed ID: 35484099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic N6-methyladenosine modification of lncRNA modulated by METTL3 during bacterial disease development in an echinoderm.
    Zhang S; Shao Y; Li D; Li C
    Fish Shellfish Immunol; 2022 May; 124():497-504. PubMed ID: 35483599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulations of m
    Chen XH; Guo KX; Li J; Xu SH; Zhu H; Yan GR
    Front Med; 2024 Aug; 18(4):622-648. PubMed ID: 38907157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA.
    Liu N; Parisien M; Dai Q; Zheng G; He C; Pan T
    RNA; 2013 Dec; 19(12):1848-56. PubMed ID: 24141618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
    Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
    Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Writers, readers, and erasers RNA modifications and drug resistance in cancer.
    Chen D; Gu X; Nurzat Y; Xu L; Li X; Wu L; Jiao H; Gao P; Zhu X; Yan D; Li S; Xue C
    Mol Cancer; 2024 Aug; 23(1):178. PubMed ID: 39215288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methyladenosine links RNA metabolism to cancer progression.
    Dai D; Wang H; Zhu L; Jin H; Wang X
    Cell Death Dis; 2018 Jan; 9(2):124. PubMed ID: 29374143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC.
    Qian X; Yang J; Qiu Q; Li X; Jiang C; Li J; Dong L; Ying K; Lu B; Chen E; Liu P; Lu Y
    J Hematol Oncol; 2021 Jul; 14(1):112. PubMed ID: 34274028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.